there have been few reports on the clinical importance of MRP8/14 as a marker of inflammatory reaction. The present study was based on our hypothesis that MRP8/14 could serve as a useful marker for active inflammation associated with monocyte/macrophage infiltration.
Sarcoidosis is a systemic disorder of unknown cause that is characterized by the presence of non-caseating granulomas in multiple organs. 13 Cardiac involvement is one of the major determinants of morbidity and mortality in patients with sarcoidosis. Thus, early diagnosis and estimation of disease activity are critically important in the treatment of cardiac sarcoidosis. However, these are often difficult, particularly in cases without any definite extra-cardiac organ involvement. [14] [15] [16] Actually, it is occasionally experienced that the correct diagnosis of cardiac sarcoidosis is done by the histological examination of myocardial specimens after autopsy or heart surgery. 17 Furthermore, in the course of disease progression, it is sometimes quite difficult to distinguish it from idiopathic dilated cardiomyopathy (DCM).
In contrast, activated macrophages (epithelioid cells) are the main components of sarcoid granulomas that play a crucial role in the pathogenesis and pathophysiology of sarcoidosis via various inflammatory cytokine networks. 18, 19 Thus, MRP8/14 is likely to be involved in the development of the granulomatous tissue; however, its in situ expression in the sarcoid heart has not been clarified. Elucidation of the MRP8/14 expression would be a great help for the estimation of disease activity in cardiac sarcoidosis.
Therefore, in the present study, we measured the serum levels of MRP8/14, and examined the expression of MRP 8/14 with special reference to its in situ localization, in the myocardium from patients with active cardiac sarcoidosis.
Methods

Patients and Materials
Study Population Thirty-five patients with histologically diagnosed sarcoidosis [15 men and 20 women; 53±16 (mean ± SD) years] and 23 patients with DCM (18 men and 5 women; 58±15 years) were included in the present serum MRP8/14 analysis study. In the sarcoidosis group, there were 10 patients with definite cardiac involvement (cardiac sarcoidosis). Sera from 30 normal volunteers served as controls. The clinical characteristics of the DCM and cardiac sarcoidosis patients are shown in Table 1 . Written informed consent was obtained from all patients and volunteers, and the study protocol was approved by the institutional review board.
Clinical Information Age, gender, systolic and diastolic blood pressures (mmHg), heart rate (beats/min) and New York Heart Association functional class were evaluated as the essential information. Left ventricular end-diastolic diameter and end-systolic diameter, left ventricular ejection fraction were measured using standard echocardiography. The existence of complete atrio-ventricular blocks and ventricular tachycardia were evaluated using 24-h ambulatory electrocardiogram monitoring.
Assay of Serum MRP8/14 Levels by ELISA Blood samples were centrifuged at 15,000 G for 15 min, and the resulting supernatants were stored at -80°C until analysis. We measured serum MRP8/14 levels using a sandwich enzyme-linked immunosorbent assay system as previously described. 12 
Biochemical Analysis
Plasma brain natriuretic peptide concentrations were measured using a specific immunoradiometric commercial assay kit (Shionogi, Osaka, Japan). Serum C-reactive protein (CRP) concentrations were measured using a latex agglutination immunophotometric assay. Serum angiotensin-converting enzyme (ACE) levels were measured using the Kasahara method. 20 
Histopathologic and Immunohistochemical Examination
Twelve patients with active cardiac sarcoidosis were included in this examination (6 men and 6 women; mean age, 50±10 years). Nine of the 12 patients underwent the left ventriculoplasty or mitral valvuloplasty between September 1997 and January 2006 at Shonan Kamakura General Hospital, Hayama Heart Center or Osaka Medical College Hospital, Japan, due to the diagnosis of DCM or unclassified cardiomyopathy. These patients were first diagnosed with active cardiac sarcoidosis postoperatively following histological examination of the resected myocardium. The remaining 3 patients were diagnosed with cardiac sarcoidosis during cardiac biopsy or autopsy ( with hematoxylin-eosin and observed under a light microscope.
The rabbit monoclonal anti-human MRP8/14 antibody was utilized to determine the localization of the MRP8/14. 12 Mouse monoclonal antibodies against both CD45 (a marker for lymphocytes) and CD68 (a marker for macrophages) (DAKO Japan, Kyoto, Japan) were used to identify types of infiltrating inflammatory cells. Immunoreactivity was examined using the avidin-biotin peroxidase complex method (ScyTek Laboratories, UT, USA). Finally, the reactions were optimized with diaminobenzidine chromogen and were counterstained with hematoxylin.
Statistical Analysis
Data are expressed as means ± SD for continuous variables, and as numbers (percentages) for categorical variables. Spearman's correlation analysis was performed to estimate correlations between variables. Multiple comparisons among more than 3 groups were performed using the SteelDwass's test. Comparison between 2 groups was performed by Wilcoxon rank sum test or the unpaired Student's t-test. A p value of <0.05 was considered statistically significant.
Results
Clinical Information
Between the DCM and cardiac sarcoidosis groups, statistical differences were observed in gender; treatment with ACE inhibitors/angiotensin II receptor blockers, and blockers; the presence of a complete atrio-venricular block; systolic blood pressure; heart rate; and serum levels of ACE and CRP (Table 1) .
Measurements of Serum MRP8/14 Levels
Serum MRP8/14 levels were significantly higher in patients with sarcoidosis than those in normal controls (515±549 vs 230±115 ng/ml, p=0.0019) and tended to be higher than those in DCM (vs 252±108 ng/ml, p=0.1224) (figure not shown). In the sarcoidosis group, serum MRP 8/14 levels were 974±838 ng/ml in patients with definite cardiac involvement (n=10), being significantly higher than 332±204 ng/ml (p=0.0227) in patients without cardiac involvement (n=25) (Fig 1) . Serum MRP8/14 levels in cardiac sarcoidosis patients were also significantly higher than in DCM patients (vs 252±108 ng/ml, p=0.0026) and normal controls (vs 230±115 ng/ml, p=0.0020) (Fig 1) . All 10 cases with definite cardiac involvement in the present study presented DCM-like clinical features. In the sarcoidosis group, there was no significant correlation between the serum MRP8/14 and ACE levels (data not shown).
Histopathologic and Immunohistochemical Examination
General Features Large non-caseating sarcoid granulomas were observed in sections from all sarcoidosis patients. They were mainly composed of lymphocytes, macrophages, multinucleated giant cells and interstitial components. Lymphocytes were mostly positive for CD45, while macrophages and giant cells were positive for CD68. Cardiomyocytes adjacent to the sarcoid granulomas were occasionally found to be degenerative or necrotic (Figs 2a,b) .
In DCM hearts, moderate to severe interstitial fibrosis and fatty infiltration were generally observed. Adjacent to interstitial fibrosis, the cardiomyocytes occasionally exhibited cytoplasmic vacuolization, scarcity of myofibrils, atrophy Table 1 .
Serum myeloid-related protein (MRP) 8/14 levels in the sarcoidosis patients with definite cardiac involvement (n=10) were 974±838 ng/ml, being significantly higher than 332±204 ng/ml (p=0.0227) in patients without cardiac involvement (n=25). Serum MRP8/14 levels in cardiac sarcoidosis patients were also significantly higher than in dilated cardiomyopathy (DCM) patients (vs 252± 108 ng/ml, p=0.0026) and in normal controls (vs 230±115 ng/ml, p=0.0020).
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or hypertrophy in size and nuclear alterations.
Expression of MRP8/14
In DCM hearts, expression of the MRP8/14 was generally negative or weak. Weak MRP8/14-positive staining was occasionally observed in mononuclear interstitial cells. In the myocardium of cardiac sarcoidosis patients, the MRP8/14 was specifically and strongly positive in the cytoplasm of macrophages, and mildly positive in multinucleated giant cells in the granulomas (Figs 2e,f) .
Discussion
Recent studies have demonstrated the significance of the expression of cytokines in the pathogenesis of sarcoidosis. 15, 18 Moller et al described that sarcoidosis is an antigendriven type 1 helper T cell (Th1)-mediated delayed-type hypersensitivity, dominated by the expression of IL-12 and IFN-. 19, 21 Preferential expression of Th1 cytokines has been reported in bronchoalveolar lavage cells and fluids in patients with pulmonary sarcoidosis. 21, 22 Thus, in the Th1 cytokine networks in sarcoid granulomas, activated macrophages (epithelioid cells) play a crucial role in the pathogenesis and pathophysiology of sarcoidosis.
In the present study, strong expression of the MRP8/14 in macrophages was demonstrated in the immunohistochemistry in granulomas of cardiac sarcoidosis, suggesting that the MRP8/14, produced by macrophages and giant cells, may play an important role in the pathogenesis of granulomas in active cardiac sarcoidosis. To our knowledge, this is the first report describing the in situ localization of MRP8/14 in the sarcoid heart.
It has been shown that increased serum concentration of MRP8/14 is an useful biomarker of disease activity in inflammatory disorders, such as inflammatory bowel disease, inflammatory muscle disease, rheumatoid arthritis, Kawasaki disease and transplant rejection. 12, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Patients with diabetes mellitus have high plasma levels of MRP8/14. 33 Most recently, it has been reported that increasing plasma concentrations of MRP8/14 among healthy individuals can predict the risk of future cardiovascular events. 34 In the present study, the serum MRP8/14 levels were significantly higher in patients with sarcoidosis than in normal controls. Thus, the serum MRP8/14 levels may be indicative of the activity of granulomatous inflammation in sarcoidosis. Furthermore, in the sarcoidosis group, the serum MRP8/14 levels were significantly higher in patients with definite cardiac involvement than in patients without. It is likely that the high serum MRP8/14 levels are due to the inflammatory response associated with cardiac sarcoidosis. The reason why the serum MRP8/14 levels were higher in patients with cardiac involvement is not clear. One possible reason may be that the number of activated macrophages -that is, amount of active sarcoid granulomas -was much larger in the heart than in other organs such as eye and skin lesions.
Three of 10 cardiac sarcoidosis patients in the serum MRP8/14 analysis study were included in the histopathologic and immunohistochemical study of the myocardium after cardiac surgery (Cases 6, 8 and 10 in Table 2 ). Two of them (Cases 6 and 8) showed extremely high serum MRP8/14 levels (Fig 1) . In both cases, heart failure progressed acutely in a few months and histological examination revealed severe and active sarcoid granulomas in the myocardium, that could be called fulminant cardiac sarcoidosis. Immunohistochemistry showed extremely enhanced ex- pression of MRP8/14 in macrophages and giant cells in the granulomas, which may be related to higher serum MRP 8/14 levels in these cases.
In some patients in the present study, biopsies of the cervical and mediastinal lymphnodes were conducted. The immunohistochemistry revealed enhanced expression of MRP8/14 in macrophages and multinucleated giant cells in the sarcoid granulomas in these lymph nodes. Thus, it is likely that enhanced expression of MRP8/14 is observed in other sarcoidosis tissues such as lung, lymph node or skin lesions. It should be kept in mind that MRP8/14 is not a heart-specific protein, and the higher serum levels do not necessarily represent active sarcoid granulomas only in the heart.
In all cardiac sarcoidosis patients of the serum MRP8/14 analysis study, the blood sampling was performed at the time of histopathological examinations, such as endomyocardial biopsy or cardiac surgery before steroid therapy. Hirono et al have reported that the serum MRP8/14 levels were upregulated during the early stages of acute Kawasaki disease, and decreased after intravenous immune globulin therapy. 31 In sarcoidosis patients, it may also be possible that serum levels of MRP8/14 could become useful markers of disease activity.
In the clinical characteristics, ACE serum levels were significantly higher in the cardiac sarcoidosis group than that in DCM group. The serum level of ACE may be a useful marker to differentiate cardiac sarcoidosis from DCM. In contrast, there was no significant correlation between the serum MRP8/14 and ACE levels in the sarcoidosis group (data not shown). The mechanisms of upregulation of MRP8/14 and ACE may be different in sarcoidosis; however, the reason for this is not clear. The evaluation of the superiority of either MRP8/14 or ACE as a biomarker of sarcoidosis will be an interesting study in the future.
All cases with cardiac involvement in the present study presented DCM-like clinical features. It is not easy to confirm the diagnosis of cardiac sarcoidosis, particularly when there is no apparent extra-cardiac involvement. Furthermore, during the course of disease progression, it is often difficult to distinguish it from DCM. Actually, as in cases in the present study, the diagnosis of cardiac sarcoidosis occasionally missed, even in a country like Japan, where this condition seems to be relatively prevalent. 35 Most diagnostic tests, including endomyocardial biopsy, suffer from low sensitivity, low specificity or both. 16 The most accurate diagnostic strategy for this condition is currently unknown. Thus, a valuable diagnostic marker would be extremely useful and is anticipated. Because serum MRP8/14 levels were significantly higher in patients with cardiac sarcoidosis than in DCM patients, and MRP8/14 expression is limited to areas with well-formed, active noncaseating granulomas in the myocardium, it may be suggested that enhanced expression of this protein could either confirm the diagnosis of cardiac sarcoidosis or estimate disease activity, particularly when there is no apparent extra-cardiac involvement. All cardiac sarcoidosis patients included in the present study have already deteriorated to relatively advanced cardiac dysfunction. Thus, the results of the present study may apply to the detection of serious cardiac involvement in sarcoidosis. Further investigations of the measurement of serum MRP8/14 for the early detection of cardiac involvement in sarcoidosis will be necessary.
In conclusion, the MRP8/14, produced by macrophages and multinucleated giant cells, is involved in the pathogenesis of sarcoid granulomas. The measurement of serum MRP8/14 levels may be useful for the diagnosis of sarcoidosis, and their higher levels may suggest the cardiac involvement.
Study Limitations
In the present study of serum MRP8/14 measurements, the sarcoidosis group without definite cardiac involvement (n=25) included patients with eye, skin, lung or lymph nodes lesions. Most of them were relatively stable patients who had been followed up at an out-patient clinic, with or without the history of steroid therapy, suggesting that their sarcoid lesions might be inactive. In contrast, most patients with definite cardiac involvement were in progressive conditions with probable active sarcoid lesions before steroid treatment. That may be one reason why there was a significant difference in serum MRP8/14 levels between the 2 groups. Further investigations with larger numbers of patients are warranted, including the information on preand post-steroid therapy to confirm the value of serum MRP8/14 measurements.
